A study has shown that up to 67% of people who stop using GLP-1 RAs regain a significant portion of the weight they lost, on average, regaining about two-thirds of their weight within a year
Secure Global Logistics: We utilize specialized packing techniques to safeguard temperature-sensitive shipments across international transit lanes
Subjects and methods In this propensity score matched cohort study on nationwide data, patients with T2D and severe obesity who underwent MBS in Sweden from 2007 until 2019 were identified from the Scandinavian Obesity Surgery Registry and matched to a non-surgical group with T2D treated with GLP-1 RA (81.7% liraglutide, 9.0% dulaglutide, 6.0% exenatide, 1.6% lixisenatide and 0.8% semaglutide) from the general population using generalized linear model
TRICARE coverage of GLP-1 medications tied to weight loss has never been for cosmetic purposes
Patients with diabetes or insulin resistance should be monitored more closely during sermorelin therapy
Award-Winning Innovator: Recipient of the IHRSA Institute Award for pioneering the first Exercise and Cancer Program and the Outstanding Leadership Award at Health 2.0 for his contributions to wellness education